| Megan L Stutheit, FNP-C | |
|
440 Hometown Plaza Dr, Owensville, MO 65066-1596 | |
| (573) 437-6100 | |
| Not Available |
| Full Name | Megan L Stutheit |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 5 Years |
| Location | 440 Hometown Plaza Dr, Owensville, Missouri |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972155232 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 2019022253 (Missouri) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | 2019022253 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercy Hospital Washington | Washington, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Western Missouri Medical Center | 4183904865 | 10 |
| Western Missouri Medical Center | 5092852111 | 12 |
| Mercy Clinic East Communities | 7214827922 | 491 |
News Archive
Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that it has launched an enhanced dental drug interactions screening tool with a new Medication Safety Check feature, allowing professionals to screen for drug-drug, drug-allergy, and duplicate therapy interactions and review safe medication options.
Pediatric cancer specialists at The Children's Hospital at Montefiore (CHAM) are investigating a new type of inhalation chemotherapy with the potential to treat children with a deadly bone cancer that has spread to their lungs.
Anadys Pharmaceuticals, announced today that dosing has begun in the Phase IIb study of ANA598 in combination with pegylated interferon and ribavirin in hepatitis C patients.
Micromet, Inc. announced today the closing of its previously announced underwritten public offering. Prior to closing, the underwriters exercised in full their option to purchase an additional 1.5 million shares of common stock. As a result, Micromet sold a total of 11.5 million shares of its common stock at a public offering price of $7.00 per share.
› Verified 5 days ago
| Entity Name | Western Missouri Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083601330 PECOS PAC ID: 7416931506 Enrollment ID: O20040616000777 |
News Archive
Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that it has launched an enhanced dental drug interactions screening tool with a new Medication Safety Check feature, allowing professionals to screen for drug-drug, drug-allergy, and duplicate therapy interactions and review safe medication options.
Pediatric cancer specialists at The Children's Hospital at Montefiore (CHAM) are investigating a new type of inhalation chemotherapy with the potential to treat children with a deadly bone cancer that has spread to their lungs.
Anadys Pharmaceuticals, announced today that dosing has begun in the Phase IIb study of ANA598 in combination with pegylated interferon and ribavirin in hepatitis C patients.
Micromet, Inc. announced today the closing of its previously announced underwritten public offering. Prior to closing, the underwriters exercised in full their option to purchase an additional 1.5 million shares of common stock. As a result, Micromet sold a total of 11.5 million shares of its common stock at a public offering price of $7.00 per share.
› Verified 5 days ago
| Entity Name | Mercy Clinic East Communities |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073739041 PECOS PAC ID: 7214827922 Enrollment ID: O20070521000058 |
News Archive
Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that it has launched an enhanced dental drug interactions screening tool with a new Medication Safety Check feature, allowing professionals to screen for drug-drug, drug-allergy, and duplicate therapy interactions and review safe medication options.
Pediatric cancer specialists at The Children's Hospital at Montefiore (CHAM) are investigating a new type of inhalation chemotherapy with the potential to treat children with a deadly bone cancer that has spread to their lungs.
Anadys Pharmaceuticals, announced today that dosing has begun in the Phase IIb study of ANA598 in combination with pegylated interferon and ribavirin in hepatitis C patients.
Micromet, Inc. announced today the closing of its previously announced underwritten public offering. Prior to closing, the underwriters exercised in full their option to purchase an additional 1.5 million shares of common stock. As a result, Micromet sold a total of 11.5 million shares of its common stock at a public offering price of $7.00 per share.
› Verified 5 days ago
| Entity Name | Western Missouri Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215388293 PECOS PAC ID: 5092852111 Enrollment ID: O20091022000298 |
News Archive
Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that it has launched an enhanced dental drug interactions screening tool with a new Medication Safety Check feature, allowing professionals to screen for drug-drug, drug-allergy, and duplicate therapy interactions and review safe medication options.
Pediatric cancer specialists at The Children's Hospital at Montefiore (CHAM) are investigating a new type of inhalation chemotherapy with the potential to treat children with a deadly bone cancer that has spread to their lungs.
Anadys Pharmaceuticals, announced today that dosing has begun in the Phase IIb study of ANA598 in combination with pegylated interferon and ribavirin in hepatitis C patients.
Micromet, Inc. announced today the closing of its previously announced underwritten public offering. Prior to closing, the underwriters exercised in full their option to purchase an additional 1.5 million shares of common stock. As a result, Micromet sold a total of 11.5 million shares of its common stock at a public offering price of $7.00 per share.
› Verified 5 days ago
| Entity Name | Western Missouri Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194275362 PECOS PAC ID: 4183904865 Enrollment ID: O20170512001582 |
News Archive
Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that it has launched an enhanced dental drug interactions screening tool with a new Medication Safety Check feature, allowing professionals to screen for drug-drug, drug-allergy, and duplicate therapy interactions and review safe medication options.
Pediatric cancer specialists at The Children's Hospital at Montefiore (CHAM) are investigating a new type of inhalation chemotherapy with the potential to treat children with a deadly bone cancer that has spread to their lungs.
Anadys Pharmaceuticals, announced today that dosing has begun in the Phase IIb study of ANA598 in combination with pegylated interferon and ribavirin in hepatitis C patients.
Micromet, Inc. announced today the closing of its previously announced underwritten public offering. Prior to closing, the underwriters exercised in full their option to purchase an additional 1.5 million shares of common stock. As a result, Micromet sold a total of 11.5 million shares of its common stock at a public offering price of $7.00 per share.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Megan L Stutheit, FNP-C 440 Hometown Plaza Dr Unit A, Owensville, MO 65066-1596 Ph: (573) 437-6100 | Megan L Stutheit, FNP-C 440 Hometown Plaza Dr, Owensville, MO 65066-1596 Ph: (573) 437-6100 |
News Archive
Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that it has launched an enhanced dental drug interactions screening tool with a new Medication Safety Check feature, allowing professionals to screen for drug-drug, drug-allergy, and duplicate therapy interactions and review safe medication options.
Pediatric cancer specialists at The Children's Hospital at Montefiore (CHAM) are investigating a new type of inhalation chemotherapy with the potential to treat children with a deadly bone cancer that has spread to their lungs.
Anadys Pharmaceuticals, announced today that dosing has begun in the Phase IIb study of ANA598 in combination with pegylated interferon and ribavirin in hepatitis C patients.
Micromet, Inc. announced today the closing of its previously announced underwritten public offering. Prior to closing, the underwriters exercised in full their option to purchase an additional 1.5 million shares of common stock. As a result, Micromet sold a total of 11.5 million shares of its common stock at a public offering price of $7.00 per share.
› Verified 5 days ago